JP2015535831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535831A5 JP2015535831A5 JP2015533466A JP2015533466A JP2015535831A5 JP 2015535831 A5 JP2015535831 A5 JP 2015535831A5 JP 2015533466 A JP2015533466 A JP 2015533466A JP 2015533466 A JP2015533466 A JP 2015533466A JP 2015535831 A5 JP2015535831 A5 JP 2015535831A5
- Authority
- JP
- Japan
- Prior art keywords
- atoms
- formula
- pharmaceutically acceptable
- tautomer
- replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- -1 4-isopropyl-1-piperazinyl Chemical group 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005959 diazepanyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000000466 oxiranyl group Chemical group 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 125000001033 ether group Chemical group 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000028412 nervous system injury Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12006707 | 2012-09-26 | ||
| EP12006707.9 | 2012-09-26 | ||
| PCT/EP2013/002577 WO2014048532A1 (en) | 2012-09-26 | 2013-08-27 | Quinazolinone derivatives as parp inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535831A JP2015535831A (ja) | 2015-12-17 |
| JP2015535831A5 true JP2015535831A5 (OSRAM) | 2016-10-20 |
| JP6276769B2 JP6276769B2 (ja) | 2018-02-07 |
Family
ID=47002492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533466A Active JP6276769B2 (ja) | 2012-09-26 | 2013-08-27 | Ｐａｒｐインヒビターとしてのキナゾリノン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9388142B2 (OSRAM) |
| EP (1) | EP2900643B1 (OSRAM) |
| JP (1) | JP6276769B2 (OSRAM) |
| KR (1) | KR102200628B1 (OSRAM) |
| CN (1) | CN104662006B (OSRAM) |
| AR (1) | AR092670A1 (OSRAM) |
| AU (1) | AU2013324681B2 (OSRAM) |
| BR (1) | BR112015006524A8 (OSRAM) |
| CA (1) | CA2886000C (OSRAM) |
| ES (1) | ES2654464T3 (OSRAM) |
| IL (1) | IL237840A (OSRAM) |
| MX (1) | MX362855B (OSRAM) |
| RU (1) | RU2650107C2 (OSRAM) |
| SG (1) | SG11201502120XA (OSRAM) |
| WO (1) | WO2014048532A1 (OSRAM) |
| ZA (1) | ZA201502838B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012358803C1 (en) | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| KR102104144B1 (ko) | 2012-03-07 | 2020-04-23 | 디 인스티튜트 오브 캔서 리서치:로얄 캔서 하스피틀 | 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도 |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| JP6284547B2 (ja) | 2012-12-21 | 2018-02-28 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| WO2015036759A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN107427506A (zh) | 2014-10-14 | 2017-12-01 | 拉霍拉敏感及免疫学研究所 | 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途 |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| CN107286169B (zh) * | 2016-04-05 | 2020-11-24 | 北京四环制药有限公司 | 端锚聚合酶抑制剂 |
| CN106432103A (zh) * | 2016-09-14 | 2017-02-22 | 信阳师范学院 | 一种喹唑酮类化合物及其制备方法 |
| EP3619210A4 (en) * | 2017-05-01 | 2020-12-02 | Sanford Burnham Prebys Medical Discovery Institute | LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND ASSOCIATED USES |
| ES2998084T3 (en) | 2017-12-27 | 2025-02-19 | Japanese Found For Cancer Res | Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor |
| WO2019131794A1 (ja) * | 2017-12-27 | 2019-07-04 | 公益財団法人がん研究会 | 抗がん剤 |
| WO2021037868A1 (en) * | 2019-08-28 | 2021-03-04 | F. Hoffmann-La Roche Ag | Novel quinazoline compounds for the treatment and prophylaxis of hepatitis b virus disease |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025221809A1 (en) * | 2024-04-16 | 2025-10-23 | Eluciderm Inc. | 2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3046871A1 (de) * | 1980-12-12 | 1982-07-22 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue chinazolinone, ihre herstellung und ihre verwendung als arzneimittel |
| EP0054132B1 (de) * | 1980-12-12 | 1984-10-10 | Dr. Karl Thomae GmbH | Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9702701D0 (en) * | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| EP1020445B1 (en) | 1997-10-02 | 2008-08-13 | Eisai R&D Management Co., Ltd. | Fused pyridine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| WO2004014873A1 (ja) * | 2002-08-09 | 2004-02-19 | Kyorin Pharmaceutical Co., Ltd. | 4-置換キナゾリン-8-カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| ATE527243T1 (de) * | 2005-03-09 | 2011-10-15 | Merck Sharp & Dohme | Calciumkanal-antagonisten vom typ chinazolinon t |
| ES2381446T3 (es) | 2007-03-08 | 2012-05-28 | Janssen Pharmaceutica, N.V. | Derivado de quinolinona como inhibidores de PARP y TANK |
| CN105859639A (zh) * | 2009-03-18 | 2016-08-17 | 雷斯韦洛吉克斯公司 | 新的抗炎剂 |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| CN103228141B (zh) * | 2010-09-03 | 2016-04-20 | 拜耳知识产权有限责任公司 | 取代的稠合的嘧啶酮和二氢嘧啶酮 |
-
2013
- 2013-08-27 RU RU2015115576A patent/RU2650107C2/ru active
- 2013-08-27 SG SG11201502120XA patent/SG11201502120XA/en unknown
- 2013-08-27 AU AU2013324681A patent/AU2013324681B2/en active Active
- 2013-08-27 BR BR112015006524A patent/BR112015006524A8/pt not_active Application Discontinuation
- 2013-08-27 ES ES13756318.5T patent/ES2654464T3/es active Active
- 2013-08-27 JP JP2015533466A patent/JP6276769B2/ja active Active
- 2013-08-27 MX MX2015003570A patent/MX362855B/es active IP Right Grant
- 2013-08-27 WO PCT/EP2013/002577 patent/WO2014048532A1/en not_active Ceased
- 2013-08-27 US US14/431,632 patent/US9388142B2/en active Active
- 2013-08-27 EP EP13756318.5A patent/EP2900643B1/en active Active
- 2013-08-27 CN CN201380050421.9A patent/CN104662006B/zh active Active
- 2013-08-27 KR KR1020157010728A patent/KR102200628B1/ko not_active Expired - Fee Related
- 2013-08-27 CA CA2886000A patent/CA2886000C/en active Active
- 2013-09-25 AR ARP130103430A patent/AR092670A1/es active IP Right Grant
-
2015
- 2015-03-19 IL IL237840A patent/IL237840A/en active IP Right Grant
- 2015-04-24 ZA ZA2015/02838A patent/ZA201502838B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535831A5 (OSRAM) | ||
| RU2015115576A (ru) | Производные хиназолинона в качестве ингибиторов parp | |
| JP2015524450A5 (OSRAM) | ||
| JP2015515961A5 (OSRAM) | ||
| JP2015511609A5 (OSRAM) | ||
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| JP2015529229A5 (OSRAM) | ||
| JP2015509512A5 (OSRAM) | ||
| JP2020097596A5 (OSRAM) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2015508103A5 (OSRAM) | ||
| JP2014507421A5 (OSRAM) | ||
| RU2015143672A (ru) | Органические соединения | |
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| HRP20161033T1 (hr) | Derivati pirolotriazinona | |
| CO2018005854A2 (es) | Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos | |
| JP2016513737A5 (OSRAM) | ||
| RU2015107733A (ru) | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения | |
| JP2013541503A5 (OSRAM) | ||
| HRP20171053T1 (hr) | Derivati oksokinazolinil-butanamida | |
| JP2011530545A5 (OSRAM) | ||
| JP2018109017A5 (OSRAM) | ||
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| JP2011518202A5 (OSRAM) | ||
| RU2015134420A (ru) | Кристаллические формы { [1-циано-5-(4-хлорофеноксид)-4-гидроксид-изохинолин-3-карбонил]-амино} -уксусной кислоты |